EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV

Naveenchandra Suryadevara, Nurgun Kose, Sandhya Bangaru, Elad Binshtein, Jennifer Munt, David R Martinez, Alexandra Schäfer, Luke Myers, Trevor D Scobey, Robert H Carnahan, Andrew B Ward, Ralph S Baric und 1 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci178880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Naveenchandra Suryadevara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Antibodies, Monoclonal, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, Defense Sciences Office, DARPA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The function of the spike protein N terminal domain (NTD) in coronavirus (CoV) infections is poorly understood. However, some rare antibodies that target the SARS-CoV-2 NTD potently neutralize the virus. This finding suggests the NTD may contribute, in part, to protective immunity. Pansarbecovirus antibodies are desirable for broad protection, but the NTD region of SARS-CoV and SARS-CoV-2 exhibit a high level of sequence divergence; therefore, cross-reactive NTD-specific antibodies are unexpected, and there is no structure of a SARS-CoV NTD-specific antibody in complex with NTD. Here, we report a monoclonal antibody COV1-65, encoded by the IGHV1-69 gene, that recognizes the NTD of SARS-CoV S protein. A prophylaxis study showed the mAb COV1-65 prevented disease when administered before SARS-CoV challenge of BALB/c mice, an effect that requires intact fragment crystallizable region (Fc) effector functions for optimal protection in vivo. The footprint on the S protein of COV1-65 is near to functional components of the S2 fusion machinery, and the selection of COV1-65 escape mutant viruses identified critical residues Y886H and Q974H, which likely affect the epitope through allosteric effects. Structural features of the mAb COV1-65–SARS-CoV antigen interaction suggest critical antigenic determinants that should be considered in the rational design of sarbecovirus vaccine candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusAntibodies, MonoclonalSARS-CoV-2Antibodies, ViralAntigens, ViralHumansAnimalsMiceMice, Inbred BALB CCOVID-19FemaleProtein DomainsEpitopesAntibodies, Neutralizing

Stichwörter der Autor:innen

Adaptive immunityImmunoglobulinsImmunologyStructural biologyVirology

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, Monoclonalspike protein, SARS-CoV-2Antibodies, ViralEpitopesAntibodies, NeutralizingAntigens, Viral

Autor:innen und Institutionen

  • Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
  • Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • Defense Sciences Office, DARPA

Zitieren

APA

Suryadevara, N., Kose, N., Bangaru, S., Binshtein, E., Munt, J., Martinez, D. R., Schäfer, A., Myers, L., Scobey, T. D., Carnahan, R. H., Ward, A. B., Baric, R. S., & Crowe, J. E. (2025). Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV. Journal of Clinical Investigation. https://doi.org/10.1172/jci178880

Vancouver

Suryadevara N, Kose N, Bangaru S, Binshtein E, Munt J, Martinez DR, et al. Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV. Journal of Clinical Investigation. 2025. doi:10.1172/jci178880

BibTeX
@article{Suryadevara2025,
  author = {Suryadevara, Naveenchandra and Kose, Nurgun and Bangaru, Sandhya and Binshtein, Elad and Munt, Jennifer and Martinez, David R and Schäfer, Alexandra and Myers, Luke and Scobey, Trevor D and Carnahan, Robert H and Ward, Andrew B and Baric, Ralph S and Crowe, James E},
  title = {Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci178880}
}
Kostenlos starten →